Nektar Therapeutics (NKTR) Return on Equity (2011 - 2026)

Nektar Therapeutics has reported Return on Equity for 16 years, with the latest figure at 0.0% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity rose 3.0% year-over-year to 0.0%; the trailing twelve-month figure through Mar 2026 stood at 0.0% (up 3.0% YoY), and the FY2025 full-year result was 0.02%, down 1.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.0%, up from 0.02% in the prior quarter.
• The five-year high for Return on Equity was 0.22% in Q2 2025, with the low at 0.04% in Q3 2025.
• Average Return on Equity over 5 years is 0.0%, with a median of 0.01% recorded in 2023.
• Peak annual rise in Return on Equity reached 24 bps in 2025, while the deepest fall reached 2 bps in 2025.
• Tracing NKTR's Return on Equity over 5 years: stood at 0.01% in 2022, then slumped by 100 bps to 0.02% in 2023, then decreased by 15 bps to 0.02% in 2024, then increased by 18 bps to 0.02% in 2025, then jumped by 74 bps to 0.0% in 2026.
• The last three Return on Equity figures came in at 0.0% (Q1 2026), 0.02% (Q4 2025), and 0.04% (Q3 2025), per Business Quant data.

Peer Comparison